【DPHARMA 7148 交流专区】（前名 CCMDBIO）

icy97

DUOPHARMA BIOTECH BERHAD

Particulars of substantial Securities Holder

Name	PERMODALAN NASIONAL BERHAD
Address	Tingkat 4, Balai PNB, 201-A, Jalan Tun Razak, Kuala Lumpur 50400 Wilayah Persekutuan Malaysia.
Company No.	197801001190 (38218-X)
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	13 Aug 2020	11,285,007	Others	Direct Interest
	Name of registered holder	PERMODALAN NASIONAL BERHAD
	Address of registered holder	TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR.
	Description of "Others" Type of Transaction	DRP

Circumstances by reason of which change has occurred	Elected to reinvest in 11,285,007 new shares pursuant to the Dividend Reinvestment Plan ("DRP").
Nature of interest	Direct Interest
Direct (units)	329,522,228
Direct (%)	46.673
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	329,522,228
Date of notice	13 Aug 2020
Date notice received by Listed Issuer	17 Aug 2020

Name	EMPLOYEES PROVIDENT FUND BOARD
Address	TINGKAT 19, BANGUNAN KWSP, JALAN RAJA LAUT KUALA LUMPUR 50350 Wilayah Persekutuan Malaysia.
Company No.	EPF ACT 1991
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	13 Aug 2020	1,504,512	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Tempatan) Sdn. Bhd.
	Address of registered holder	Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur.
	Description of "Others" Type of Transaction	DRP
2	13 Aug 2020	116,570	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Tempatan) Sdn. Bhd.
	Address of registered holder	Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur.
	Description of "Others" Type of Transaction	DRP
3	13 Aug 2020	557,415	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Tempatan) Sdn. Bhd.
	Address of registered holder	Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur.
	Description of "Others" Type of Transaction	DRP
4	13 Aug 2020	58,039	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Tempatan) Sdn. Bhd.
	Address of registered holder	Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur.
	Description of "Others" Type of Transaction	DRP
5	13 Aug 2020	37,652	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Tempatan) Sdn. Bhd.
	Address of registered holder	Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur.
	Description of "Others" Type of Transaction	DRP

Circumstances by reason of which change has occurred	(1) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board(Elected to reinvest in 1,504,512 new shares pursuant to the Dividend Reinvestment Plan ("DRP")).(2) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (AM INV)(Elected to reinvest in 116,570 new shares pursuant to the DRP).(3) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (CIMB PRI) (Elected to reinvest in 557,415 new shares pursuant to the DRP).(4) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (ABERISLAMIC) IC.(Elected to reinvest in 58,039 new shares pursuant to the DRP).(5) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (NIAM EQ) IC.(Elected to reinvest in 37,652 new shares pursuant to the DRP).
Nature of interest	Indirect Interest
Direct (units)
Direct (%)
Indirect/deemed interest (units)	53,143,077
Indirect/deemed interest (%)	7.527
Total no of securities after change	53,143,077
Date of notice	14 Aug 2020
Date notice received by Listed Issuer	18 Aug 2020

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	133,772	142,855	435,816	438,707
2	Profit/(loss) before tax	18,568	19,768	55,686	56,870
3	Profit/(loss) for the period	14,127	14,859	42,417	43,240
4	Profit/(loss) attributable to ordinary equity holders of the parent	14,127	14,859	42,417	43,240
5	Basic earnings/(loss) per share (Subunit)	2.03	2.20	6.16	6.49
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.50	1.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.8400		0.7700

Type	Announcement
Subject	OTHERS
Description	Duopharma Biotech Posts Another Strong Quarter Registering PBT of RM18.57 million
We attach herewith a copy of press release dated 12 November 2020. This announcement is dated 12 November 2020. Please refer attachment below.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104505

Attachments Duopharma Biotech Berhad - Press Release on Q3 2020 .pdf

Type	Announcement
Subject	OTHERS
Description	1. TERM SHEET BETWEEN THE JOINT-STOCK COMPANY "MANAGEMENT COMPANY OF RUSSIAN DIRECT INVESTMENT FUND" AND DUOPHARMA (M) SENDIRIAN BERHAD ("DMSB"), A WHOLLY-OWNED SUBSIDIARY OF DUOPHARMA BIOTECH, FOR THE DISTRIBUTION OF THE 'SPUTNIK V' VACCINE ("VACCINE") IN MALAYSIA; AND2. TERM SHEET BETWEEN THE GOVERNMENT OF MALAYSIA AND DMSB, FOR THE SUPPLY OF THE VACCINE TO THE GOVERNMENT.
The Board of Directors (the “Board”) of Duopharma Biotech Berhad (”Duopharma Biotech” or the “Company”) wishes to announce that Duopharma (M) Sendirian Berhad (“DMSB”), a wholly-owned subsidiary of the Company, had on 26 January 2021 entered into the following term sheets: (i) a term sheet with the Joint-Stock Company "Management Company of Russian Direct Investment Fund" for the distribution of the finished form of the “Sputnik V” adenovirus vector vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology for SARS-Cov-2 (COVID-19) (the “Vaccine”) in Malaysia; and (ii) a term sheet with the Government of Malaysia, represented by the Ministry of Health, Malaysia (the “Government”), for the supply by DMSB to the Government of the finished form of the Vaccine. Please refer to the attachment for details of the announcement. This announcement is dated 26 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3124553

Attachments Announcement- Term Sheet with RDIF with DMSB for Distribution of Sputnik Vaccine.pdf

Type	Announcement
Subject	OTHERS
Description	DUOPHARMA BIOTECH TO SUPPLY 6.4 MILLION DOSES OF THE RUSSIAN COVID-19 VACCINE TO THE NATION
We attach herewith a copy of press release dated 26 January 2021. This announcement is dated 26 January 2021. Please refer attachment below.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3124555

Attachments Press Release -Duopharma Biotech to Supply 6.4 million doses of the Russian COVID-19 Vaccine to the Nation - 26.01.2021 (Final).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	171,838	133,772	493,731	435,816
2	Profit/(loss) before tax	22,483	18,568	65,856	55,686
3	Profit/(loss) for the period	16,963	14,127	49,967	42,417
4	Profit/(loss) attributable to ordinary equity holders of the parent	16,963	14,127	49,967	42,417
5	Basic earnings/(loss) per share (Subunit)	1.80	1.52	5.31	4.59
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.50	0.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.6500		0.7000

Type	Announcement
Subject	OTHERS
Description	DUOPHARMA BIOTECH POSTS STRONG GROWTH IN 3Q 2021
We attach herewith a copy of press release dated 18 November 2021. This announcement is dated 18 November 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3210521

Attachments Press Release - Duopharma Biotech Berhad - Q3 2021 Financial Results (Final).pdf

icy97

Type	Announcement
Subject	OTHERS
Description	ACCEPTANCE OF TENDER OFFER FOR THE SUPPLY OF INSUGEN - INSULIN RECOMBINANT HUMAN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
The Board of Directors of Duopharma Biotech Berhad (“Duopharma Biotech”) wishes to announce that the Government of Malaysia had accepted the tender offer from Duopharma Marketing Sdn. Bhd. (hereinafter referred to as “DMktg”) to supply the Products under the Ministry of Health’s procurement by way of direct negotiation (hereinafter referred to as the “LOA”) upon the terms and conditions set out in the LOA. DMktg is a wholly-owned subsidiary of Duopharma Biotech. For full details of the announcement, please refer to the attached file. The announcement is dated 17 December 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3219870

Attachments Duopharma Biotech Berhad - Acceptance of Tender Offer for the Supply of Insugen - Insulin Recombinant Human Formulations to the Government of Malaysia.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	EXECUTION OF THE AGREEMENT FOR THE PROCUREMENT VIA DIRECT NEGOTIATION FOR THE SUPPLY OF INSULIN MEDICINE AS A PACKAGE ('PERJANJIAN PEROLEHAN SECARA RUNDINGAN TERUS PEMBEKALAN UBAT INSULIN SECARA PAKEJ') PURSUANT TO THE ACCEPTANCE OF TENDER OFFER FOR THE SUPPLY OF INSUGEN - INSULIN RECOMBINANT HUMAN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
We refer to the announcement by Duopharma Biotech Berhad (hereinafter referred to as “Duopharma Biotech” or the “Company”) on 25 April 2022 (hereinafter referred to as the “Announcement”) in relation to the acceptance by the Government of Malaysia (hereinafter referred to as the “Government”) of the tender offer for the supply of the Products by Duopharma Marketing Sdn. Bhd. (hereinafter referred to as “DMktg”) (a wholly-owned subsidiary of Duopharma Biotech) and Biocon Sdn Bhd. (hereinafter referred to as “Biocon”) to the Government under the Ministry of Health’s procurement by way of direct negotiation (hereinafter referred to as the “Revised Letter of Award”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcement unless otherwise defined herein. The Company wishes to announce that pursuant to the Revised Letter of Award, the formal agreement for the procurement via direct negotiation for the supply of insulin medicine as a package (‘Perjanjian Perolehan Secara Rundingan Terus Pembekalan Ubat Insulin Secara Pakej’) (hereinafter referred to as the “Agreement”) between the Government, DMktg as the Supplier/Distributor and Biocon as the manufacturer has been executed on 30 September 2022. The Agreement entered into by the Government, DMktg and Biocon for the supply of the Products is in the ordinary course of business of the Duopharma Biotech group. For full details of the announcement, please refer to the attached file. This announcement is dated 30 September 2022.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3296149

Attachments Announcement Attachment - Execution of Agreement on Procurement for Supply of Insulin.pdf

icy97

DUOPHARMA BIOTECH BERHAD

Particulars of substantial Securities Holder

Name	PERMODALAN NASIONAL BERHAD
Address	TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK KUALA LUMPUR 50400 Wilayah Persekutuan Malaysia.
Company No.	197801001190 (38218-X)
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Disposal of 10,000,000 shares by Permodalan Nasional Berhad on 27 February 2023.

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	27 Feb 2023	10,000,000	Disposed	Direct Interest
	Name of registered holder	PERMODALAN NASIONAL BERHAD
	Address of registered holder	TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Direct Interest
Nature of interest	Direct Interest
Direct (units)	409,032,712
Direct (%)	42.955
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	409,032,712
Date of notice	27 Feb 2023
Date notice received by Listed Issuer	01 Mar 2023

Name	PERMODALAN NASIONAL BERHAD
Address	TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK KUALA LUMPUR 50400 Wilayah Persekutuan Malaysia.
Company No.	197801001190 (38218-X)
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	01 Mar 2023	10,000,000	Acquired	Direct Interest
	Name of registered holder	PERMODALAN NASIONAL BERHAD
	Address of registered holder	TINGKAT 4,BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Acquisition of 10,000,000 shares by Permodalan Nasional Berhad on 1 March 2023.
Nature of interest	Direct Interest
Direct (units)	419,032,712
Direct (%)	44.005
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	419,032,712
Date of notice	01 Mar 2023
Date notice received by Listed Issuer	03 Mar 2023

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2024	30 Jun 2023	30 Jun 2024	30 Jun 2023
		$$'000	$$'000	$$'000	$$'000

1	Revenue	218,324	167,516	411,292	367,991
2	Profit/(loss) before tax	21,960	16,515	42,061	44,805
3	Profit/(loss) for the period	16,689	12,541	31,966	35,172
4	Profit/(loss) attributable to ordinary equity holders of the parent	16,689	12,541	31,966	35,172
5	Basic earnings/(loss) per share (Subunit)	1.73	1.31	3.32	3.68
6	Proposed/Declared dividend per share (Subunit)	1.00	0.50	1.00	0.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7200		0.7100

Type	Announcement
Subject	OTHERS
Description	DUOPHARMA BIOTECH RECORDS ROBUST FINANCIAL PERFORMANCE IN Q2 2024
We attach herewith a copy of the press release dated 15 August 2024. This announcement is dated 15 August 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3473841

Attachments Duopharma Biotech - Press Release Q2 2024.pdf

icy97

DUOPHARMA BIOTECH BERHAD

Entitlement subject	First Interim Dividend
Entitlement description	First Interim Dividend of 1.0 sen per ordinary share tax exempted under the single-tier system in respect of the financial year ending 31 December 2024
Ex-Date	29 Aug 2024
Entitlement date	30 Aug 2024
Entitlement time	5:00 PM
Financial Year End	31 Dec 2024
Period
Share transfer book & register of members will be	to  closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	12 Sep 2024
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	30 Aug 2024
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0100

icy97

Type	Announcement
Subject	OTHERS
Description	NEW EMPLOYMENT AGREEMENT FOR ENCIK LEONARD ARIFF BIN ABDUL SHATAR AS GROUP MANAGING DIRECTOR OF DUOPHARMA BIOTECH BERHAD
The Board of Duopharma Biotech Berhad ("Duopharma Biotech" or the "Company") is pleased to announce that a new employment agreement dated 6 September 2024 has been entered into between the Company and Encik Leonard Ariff Bin Abdul Shatar (i.e. the current Group Managing Director of the Company) ("Encik Leonard"). Both the Company and Encik Leonard have agreed for Encik Leonard to continue serving as the Group Managing Director of the Company after his current employment agreement expires in December 2024. Encik Leonard's new employment agreement will commence on 9 December 2024 until 31 December 2025 subject to and upon the terms and conditions therein contained. The Board also wishes to inform that the Company has developed a succession plan in relation to the Group Managing Director's role and is progressing under the stewardship of the Company's Nomination and Remuneration Committee so as to facilitate a smooth and effective chief executive leadership transition for the Company in due course. This announcement is dated 6 September 2024.